INDEPENDENT INTELLIGENCE
LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Beam Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBEAM
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BEAM COVERAGE

What’s moving Beam Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
Beam Therapeutics Inc. (BEAM) reports Q2 loss, lags revenue estimates

Beam Therapeutics Inc. (BEAM) reports Q2 loss, lags revenue estimates

Investors are testing whether Beam Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Beam Therapeutics Inc BEAM

Beam Therapeutics Inc BEAM

The story matters when it changes Beam Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?

Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?

Investors are testing whether Beam Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

The story matters when it changes Beam Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Investors are testing whether Beam Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BEAM filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-04 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-04 · Period 2026-08-04SEC ↗8-KMaterial company eventFiled 2026-06-08 · Period 2026-06-03SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-17 · Period 2026-06-03SEC ↗4Official SEC filingFiled 2026-07-29 · Period 2026-07-27SEC ↗
EARNINGS / QUARTERLY TRACKER

Beam Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.